ERBB2 and breast carcinoma: Additionally, PIK3CA hotspot mutations may also contribute to therapy resistance in breast cancer, with associations found between these mutations and resistance to chemotherapy (e.g., paclitaxel, anthracyclines) [64,88,89] and HER2-targeted therapies like trastuzumab [82,90,91,92].